Older age has been linked to increased transplant-related mortality from graft-versus-host disease (GvHD). Depletion of T cells from stem cell grafts seems to protect from complications of GvHD particularly in older patients. After myeloablative conditioning, patients with haematological malignancies received allogeneic grafts from HLA identical siblings. For GvHD prophylaxis, PBPC grafts were treated ex vivo with anti-CD52, and therapeutic doses of cyclosporin until day þ 90. Survival of patients younger or older than the population age median was analysed. In all, 62 consecutive patients with a median age of 42.5 years were studied. Death was procedure related in 17% and from relapse of malignancy in five. At a median, follow-up is 662 (7-2316) days, 74% survive disease free. The rate of haematopoietic recovery and treatmentrelated mortality was similar in both groups. A total of 73% of 30 individuals in the younger group and 75% (P ¼ 0.8) in the older cohort survive at a median follow-up of 444 and 806 days (P ¼ 0.4). GvHD occurred in 13% and was the only adverse factor for survival (Po0.04). Myeloablative conditioning is well tolerated up to the age of 59 in patients receiving T-cell-depleted grafts. This information is useful to more precisely select patients who would benefit most from reduced intensity conditioning schedules. Bone Marrow Transplantation (2005) 36, 675-682.
treatment of haematopoietic malignancies, particularly if an HLA-identical sibling is available. However, a number of risk factors that adversely affect patient outcome and limit its broader use have been described. These include age, [1] [2] [3] organ dysfunction, performance status, graft-versushost disease (GvHD), 4 ,5 disease status, etc. Particularly problematic is older age which is often associated with less good performance status, organ dysfunction and higher incidence and severity of GvHD. 6, 7 This is partly explained because myeloablative conditioning leads to widespread tissue damage and to the release by inflammatory cells of cytokines that enhance GvHD. Moreover, older patients have lower tolerance to the side effects of the myeloablative conditioning, resulting in higher transplant-related mortality, 8 thus limiting the wider use of myeloablative forms of conditioning for transplantation.
As an alternative, powerful immunosuppressive schedules where the dose intensity of the conditioning has been reduced (RIC) also lead to successful engraftment and may be associated with lower transplant-related complications and mortality. 9, 10 Such modalities have been associated with very high risk of particularly chronic GvHD which, in turn, leads to the need for long-term immunosuppression. 11 Also, such an approach may not be optimal for the rapid control of highly aggressive malignancies, where myeloablative doses are useful for faster disease eradication. 12 Depletion of T cell from the stem cell graft is the most effective strategy in the prevention of GvHD, even when a larger load of T cells are present, as occurs in a peripheral blood stem cell graft (peripheral blood progenitor cell (PBPC)). 13, 14 Experience has shown that lower incidence and severity of GvHD has been associated with improvement in early outcome after transplantation and may also have a favourable impact on overall survival. 13 Thus, we postulate that in older patients, haematopoietic stem cell transplantation may be more tolerable in the absence of the deleterious effects of GvHD. For this reason we reviewed the outcome of individuals with haematological malignancies who received uniform T-cell depletion of the stem cell grafts with CAMPATH-1H (alemtuzamab anti CD52) 15 antibody. We show that in the absence of clinical features of GvHD, patients can successfully undergo myeloablative conditioning up to the age of 59 years with acceptable transplantrelated mortality and good long-term control of malignancy.
Patients and methods
This study includes all consecutive adults with haematological malignancies referred for allogeneic transplantation from their HLA-identical siblings between July 1999 and October 2004. Entry criteria included adequate performance status (0, 1 or 2) nonreactivity on testing for the human immunodeficiency virus, in remission of AML or ALL, in second or further chemosensitive response of lymphoma, chronic phase CML and multiple myeloma responsive to steroid or anthracycline-containing therapies. Patients with acute myeloid leukaemia and good prognosis cytogenetic abnormalities without other adverse factors were excluded. The details of our therapies have been published elsewhere. 14, 16, 17 Preparation for transplantation Informed consent was taken from the patients according to the guidelines at Groote Schuur Hospital and the University of Cape Town. In preparation for the procedure, a double-lumen indwelling catheter was placed into a deep thoracic vein. 18 Patients were nursed in laminar down flow rooms and received oral microbiological prophylaxis with ofloxacin 200 mg bd, valocyclovir 1000 mg four times daily and co-trimoxazole 80 mg 12 hourly, twice a week. Fever 4381C unrelated to transfusions or concurrent medications mandated antibiotic treatment that included a third generation cephalosporin in combination with an aminoglycoside or glycopeptide. 19 Patients were transfused with filtered blood products to maintain the haemoglobin level above 8 g/dl and the platelet count greater than 10 Â 10 9 /l. Haematopoietic growth factors were not routinely used. Patients also received tranexamic acid as antifibrinolytic agent and low-dose warfarin. 20 
Myeloablative conditioning
Two myeloablative conditioning protocols were used during the trial. One was radiotherapy based, while the other included cytotoxic agents only. Choice of conditioning was derived from the availability of radiotherapy space in a busy tertiary hospital oncology programme. The radiation-based conditioning regimen was with fractionated (f) total body irradiation (TBI) delivered in six twice daily fractions of 2 Gy (total 1200 cGy), four fractions of total lymphoid irradiation (TNI) of 1.5 Gy followed by cyclophosphamide 60 mg/kg (with mesna cover) on days À2 and À1. 14, 16 Patients with multiple myeloma were also conditioned with radiotherapy but melphalan at 100 mg/ m 2 , replaced cyclophosphamide. When radiotherapy was not available, individuals received conditioning with oral busulfan 1 mg/kg Â 12, melphalan 70 mg/m 2 on two consecutive days (total dose 140 mg/m 2 ), followed by cyclophosphamide 120 mg/kg in two daily divided doses.
Collection of stem cells for transplantation
For the mobilisation of marrow progenitors, HLAidentical sibling donors were treated with five daily subcutaneous injections of G-CSF 5-10 mg/kg/day. Large volume apheresis was started approximately 4 h after the last dose of G-CSF. The anticoagulant was ACD-A, typically at the ratio of one volume for every 20 volumes of blood. Heparin 3000 U was added to each 500 ml unit of ACD-A. During each procedure, approximately 30 l of blood were processed. The volume of each apheresis unit was measured using a suitable automated differential cell counter and the concentration of mononuclear cells determined as the combination of blasts, lymphocytes and monocytes. The number of CD34 þ cells was determined according to the guidelines of the International Society for Haematotherapy and Graft Engineering. 21 Based on the patient's ideal body weight, the target cell dose was 2 Â 10 6 CD34 þ cells/kg. In the event that the target cell dose was not achieved, apheresis was repeated the following day. Only four donors were subjected to more than two collections. To confirm engraftment, based on sex chromosome differences between donor and recipient by standard cytogenetic analysis, we determined origin of haematopoiesis at 3 months post transplantation.
Treatment with monoclonal antibody
CAMPATH-1H was prepared from the culture supernatant of Chinese hamster ovary cell transfectants, subjected to a final purification by size exclusion chromatography on Superdex 200. 22 Stem cell-rich products were then treated with CAMPATH-1H (humanised antibody) and 10-20 mg (1-2 mg/10 8 MNC cells) was added 'into the bag', allowed to react at 201C for 30 min. The cell suspension was then infused intravenously, with no filters, over 30-60 min without further manipulation. Intravenous cyclosporin was commenced on day À1 at a dose of 3 mg/kg in two divided doses, always maintaining a therapeutic serum level. Upon recovery of the gastrointestinal tract from the effects of the conditioning, it was continued as an oral formulation until day 90. GvHD was defined according to the Seattle criteria. Acute GvHD, grades II-IV, was treated with systemic prednisone (2-10 mg/kg/day) with or without cyclosporin (according to blood levels). Once this phenomenon was controlled, immunosuppression was tapered off according to clinical response.
Statistical analysis
The w 2 statistic or Fisher's exact tests were used to establish differences in the distribution of discontinuous variables and Student's t-test to compare continuous variables. All reported P-values are two sided. Following a global analysis of outcome, results of patients younger or older than median age were compared. Characteristics of the two treatment groups and outcomes were also compared using the w 2 test for categorical variables and the MannWhitney-Wilcoxon rank sum test for continuous variables. A further study of patient outcome according to age groups was undertaken (o40, 40-49 and 449 years old) and parameters compared by analysis of variance. Overall survival (OS) estimates were obtained by the method of Kaplan and Meier, and comparisons made using the log rank test. Multifactorial nonlinear regression was used to analyse the possible relationship between survival and the /kg were harvested (Table 1) . For the ex vivo treatment of the grafts, the median dose of CAMPATH-1H employed was 10 mg (range 7.5-50). For the whole group, median followup is 622 (range 7-2316) days and 74% survive disease free.
Engraftment-and treatment-related mortality
Recovery of neutrophils was rapid, as expected in patients receiving peripheral blood stem cell transplants. Except for one who died of sepsis on day 7, all patients recovered their blood parameters after graft infusion. Median time to granulocytes 40.5 Â 10 9 /l and platelets 450 Â 10 9 /l was 11 (range 9-35) days. In all, 31 patients received a stem cell graft from an opposite gender donor. A karyotypic analysis of their marrow cells performed 3 months post transplantation showed full donor chimerism in each case.
In all, 22 (35%) patients received chemotherapy-based conditioning. Another 40 patients were conditioned with myeloablative radiotherapy-based schedules. At transplantation their respective median age was 42 years (17-59) and 45.5 years (range 17-58; P ¼ 0.2). Median follow-up for these two groups was not significantly different (836 (range 43-1523) and 608 (range 7-2316) days; P ¼ 0.7) and 68 and 77% survive. There was no difference in survival between the two conditioning groups (P ¼ 0.4). Cause of death was infection in four, VOD, and hepatic lymphoma following retransplantation for late (5 months) graft failure in a patient with CML. Of the patients who received radiationbased conditioning 10 died, three (with acute leukaemia) of disease recurrence, one as the consequence of GvHD, three of infection, one of disease recurrence and GvHD following DLI and two from idiopathic interstitial pneumonia and VOD.
Outcome according to diagnosis (Figure 1) In all, 21 patients received grafts for AML and another five for ALL. Of these 26 with acute leukaemia, at a median follow-up of 499 days (range 7-1447) two with ALL and Table 1 Clinical characteristics of patients undergoing stem cell transplantation 14,15 Three patients with CML died; one from Epstein-Barr virus-induced lymphoma of the liver after second transplant, another who failed to seek medical attention in a timely manner, from multilobar pneumonia, and the third individual of GvHD, subsequent to DLI following disease recurrence at 496 days from transplantation.
Outcome according to age
The median age of the patient population was 42.5 years (range 17-59). Survival of patients in the two groups of above or below the median age was compared. Group I represented patients younger than 42.5 years, while group II included individuals older than 42.5 years. At a median follow up of 738 (7-1857) and 609 days (41-2316), respectively, survival was 73% for the 30 individuals in group I (median age 34.5 years; Table 2 ) and 75% of 32 patients in group II (median age 50 years), respectively (P ¼ 0.6) (Figure 2 ). To determine if the subgroup of individuals older than 50 years were at an excessive risk of death that was not detected by the previous analysis, patients were also divided in three age groups: younger than 40 years (n ¼ 25) aged between 40 and 49 years (n ¼ 21) and subjects older than 49 years (n ¼ 16). Kaplan and Meier survival curves again confirmed that the outcome of patients older than 50 years was not significantly different from those younger than 40 years ( Figure 3 ).
Graft-versus-host disease
Eight patients (13%) developed grade 41 acute GvHD, which in two progressed to grade 3, and to grade 4 in one, but all improved with systemic corticosteroid treatment at doses ranging from 1 to 10 mg/kg. Five developed the chronic form and three patients required prolonged therapy with azathioprine for a median of 1 year. All these patients had at least one admission to hospital for the treatment of associated severe opportunistic infection. One patient had four admissions with various bacterial or viral infections and died of sepsis. One patient died of adenovirus viraemia and haemorrhagic cystitis complicated by Gram-negative bacterial sepsis. One patient developed de novo chronic Figure 4 ).
Disease-free survival and overall survival
Survival following haematopoietic stem cell transplantation is shown in Tables 1 and 2 . At a median follow-up of 622 days (7-2316 days) 46 patients (74%) survive disease free. At 2 years 70% of patients were alive and there were no further fatal events thereafter. Analyses focused on 2-year outcomes. Univariate analysis showed that rate of recovery of blood counts, CFU-GM dose and occurrence of GvHD were significant for survival. Multivariate analysis failed to show that age at transplantation or type of malignancy were significant for survival. Proportional hazards (Cox) regression analysis confirmed that only absence of GvHD significantly predicted for favourable outcome (and Figure 4) .
Toxicity (Table 3)
All patients developed grade 4 haematological toxicity and required transfusion support with red cells and platelets. Pyrexia requiring antibiotics was seen in 93% of patients and two died of unresponsive Candida albicans sepsis (both in age group I). Radiotherapy-based conditioning was well tolerated and only 12 patients (five in group I and seven in group II) developed gastrointestinal toxicity greater than WHO 2. Three patients (two in the younger and the third in the second age group) developed idiopathic interstitial pneumonia, which resolved following steroid therapy in one. One patient who also had idiopathic pneumonitis developed VOD. In the chemotherapy conditioning cohort, seven patients developed greater than grade 2 mucositis (three and four patients, respectively, in the two age groups) and another young individual, portal vein thrombosis, but all reversed following conventional supportive therapy. One patient developed fatal veno-occlussive disease of the liver, despite heparin prophylaxis.
Discussion
GvHD and graft rejection appear to be mirror image phenomena mediated by the immune systems of the donor or recipient, against the host or graft, respectively. If, during conditioning, immunosuppression of the host has been adequate, T cells from the donor graft consolidate, leading to successful engraftment, as seen in most myeloablative programmes. However, even in HLA-identical pairs, the occurrence of acute or chronic GvHD may result in significant morbidity and mortality from parenchymal damage. Its clinical management has remained challenging, as the intensely immunosuppressive therapies required to control this phenomenon also lead to delayed immune reconstitution and substantial infection risk. 23, 24 GvHD seems to increase in frequency and severity in older age patients. In addition, other comorbidities typically There was no significant difference in conditioning toxicity between the two age groups.
T-cell depletion of PBPC grafts N Novitzky et al associated with age contribute additive unfavourable effects increasing morbidity of the procedure and further compromising survival. It is thus not surprising that most series conclude that older age has a very significant impact on survival. Indeed, for this reasons, for allogeneic transplantation cutoff ages of 45 and 50 years have been suggested by some investigators. [25] [26] [27] [28] However, this would make transplantation unavailable as a curative option for the majority of patients with blood malignancies.
In the current study, T-cell depletion with CAMPATH-1H antibody led to excellent engraftment rates, with a low incidence of GvHD. At a median follow-up of 622 days from transplantation, 74% of patients survive. Owing to logistic reasons two myeloablative conditioning regimens were used; one was mainly radiotherapy based while the other was centred on three different alkylating agents, but between them no significant difference with regards to toxicity profile, engraftment rates and long-term survival was encountered. The two preparatory schemes were also well distributed between the two age groups.
Of note is that several patients developed fatal bacterial infections even after 6 months from transplantation, confirming previous observations that in patients receiving T-cell-depleted grafts, particularly among the older population, reconstitution of the immune system is delayed, only normalising by 18 months post transplantation. 29, 30 However, no further events were observed after 15 months follow-up. This prolonged immunosuppression may be related to the in vivo long biological life of the anti-CD52 antibody, as it has been detected in blood many months following its infusion. 31 Thus, the lowest possible dose of antibody (0.1 mg/10 8 mononuclear cells) was used for the ex vivo purging with and it rarely exceed 10 mg. 32, 14 Although Kaplan and Meier curves show that at 2 years from transplantation patients with acute leukaemia had lower survivals than did patients with CML or lymphoproliferative malignancies, this difference was not significant (Figure 2 ). This may be relevant, as patients with acute leukaemia were younger (median 34 years), than those with lymphoma (median 47.5 years; Po0.01) and CML (median 39 years; P ¼ 0.02). However, in the younger cohort, the main cause of death also remained transplant related, as only three had disease recurrence, suggesting that this modality gave effective protection from disease relapse. In support of this point, multivariate analysis confirmed that type of malignancy was not an independent factor for survival in the current study. However, as previously reported, 33, 17 in patients with CML disease recurrence was already high (450%), by 6 months when tested by molecular techniques, but all these patients responded to escalating doses of donor lymphocyte infusions, thereafter. Although one patient died of complications from GvHD, the remainder enjoyed durable remissions. For this reason, in those who test positive for the BCR/ABL chimeric gene at 6 months from transplantation it is our current practice to treat them with escalated donor lymphocyte infusion schedules until clearance of the molecular marker. In addition, we also offer DLI as prophylaxis of relapse, even if on molecular studies they have remained in remission, as it is our experience that most of them will eventually progress. 14, 17 However, in these patients we do not progress beyond the infusion of 1 Â 10 7 /kg CD3 cells. None of the patients so treated have shown evidence of disease relapse. Despite advanced disease and in two, moderate renal failure, patients with multiple myeloma did particularly well and four survive disease free at a median of 752 days, receiving no therapy. There was no disease recurrence in patients with lymphoma and all four deaths were transplant related (one fungal sepsis; one unresponsive GvHD, interstitial pneumonia and an episode of Gram (À) sepsis).
For patients receiving unfractionated PBPC grafts, significant stages of GvHD are a common complication and a substantial cause of morbidity and mortality. In our cohort, this complication was rare and was seen in 13%. Furthermore, correlation analysis confirmed that GvHD was also associated with a worse outcome (P ¼ 0.02; Figure 4 ). While in the absence of post transplant immunosuppression ex vivo T-cell depletion with CAM-PATH-1H antibodies has been highly protective for the prevention of GvHD in patients receiving bone marrow transplants, a higher incidence of this complication was noted in those receiving PBPC grafts. However, it was noted that patients with acute leukaemia had lower relapse rates. 14 We believe that the combined effects of CAM-PATH-1H 'in the bag' and post transplant cyclosporin has improved early post transplant immunosuppression and resulted in the current low rates of GvHD and relapse of malignancy.
We can therefore summarise the conclusions of our investigation as follows: (1) T-cell depletion with CAM-PATH-1H antibodies was highly protective against GvHD. (2) The low incidence of GvHD was translated into low conditioning-associated toxicity, and thus older patients had similar procedure-related mortalities as the younger cohort. This resulted in a survival rate that was not significantly different between the study groups. (3) Although the patients numbers were low, when patients were further split into ages younger than 40, 40-49 years and patients older than 49 years, again no significant difference in outcome was noted in any of the three age groups (Figure 3) .
Recently, a number of investigators have described reduced intensity conditioning schedules that induced powerful immunosuppressive effects but as these were not ablative, led to low toxicity but still high engraftment rates. While for the more indolent disorders there was good disease control, it appeared less successful in those who suffered from aggressive malignancies. 2, [34] [35] [36] [37] A further complicating factor is that most individuals developed extensive GvHD and required prolonged therapy with immunosuppressive agents. The high consequent risk of opportunistic infections results in further adverse factors for survival. 38 In addition, within this group, old age may also be an independent unfavourable survival factor. Canals et al 39 compared the outcome of patients transplanted following myeloablative conditioning and T-cell depletion by CD34 þ selection with another matched group who received RIC and unfractionated grafts. In the latter group nonrelapse mortality at 1 year was substantial (39%) and mainly due to infections. Treatment-related mortality with this method would seem to be higher than with CAMPATH-1H antibodies. 13, 14 In the second group, T-cell depletion of PBPC grafts N Novitzky et al mortality was similar to the current report, and was mainly caused by GvHD and related infections (15%).
To be able to choose the best modality for an individual patient, all these alternatives require scrutiny based on prospective trials, but currently, such data are still not available. In the interim, one alternative would be to extend myeloablative T-cell-depleted transplantation up to the age of 60 years in patients who have adequate performance status, as with such an approach we can expect long-term survivals of about 70%. Patients with contraindications to high-dose conditioning schedules such as previous myeloablative conditioning or organ dysfunction, but who have indolent malignancies (chemotherapy responsive follicular lymphomas, etc) would be ideal candidates to receive RIC.
In conclusion, by reducing the risk and severity of GvHD, in patients with adequate performance status, myeloablative doses of conditioning followed by ex vivo Tcell depletion with anti-CD52 was well tolerated up to the age of 59 years, without increase in morbidity or mortality. However, the specific place of each modality will require the guidance of prospectively conducted controlled trials.
